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The Nox ﬁeld (for review see [3, 4] has seen two distinct
epochs: (1) the Age of the Phagocyte Oxidase, which began
in earnest more than 30 years ago, during which the
respiratory burst oxidase was believed to be the sole
‘‘professional’’ generator of reactive oxygen species
(ROS), the production of which was thought to be largely
conﬁned to phagocytic cells, and (2) the Age of the Nox
Family, which began around the turn of the 21st century
and which showed the existence of multiple Nox isoen-
zymes. The Age of the Phagocyte Oxidase revealed that
an NADPH-dependent, superoxide-generating respiratory
burst oxidase is essential for microbial killing by phago-
cytes, elucidated the key catalytic (Nox2) and regulatory
(p22phox, p47phox, p67phox, p40phox, Rac) subunits that
control this enzyme, and showed that the genetic absence
or mutation of individual NADPH oxidase components
causes chronic granulomatous disease wherein affected
individuals are prone to frequent, unusual infections.
During the subsequent Age of the Nox Family, it was
discovered that there are multiple Nox isoenzymes (seven
in human—Nox1, Nox2, Nox3, Nox4, Nox5, Duox1, and
Duox2—plus many more that are widely distributed among
virtually all eukaryotic organisms from fungus to verte-
brates), that they exist in a variety of cell types/tissues, and
that they show varied mechanisms of activation. Mostly
during the 1990s (prior to and leading up to the second Nox
epoch) investigators in diverse ﬁelds had observed that
superoxide or hydrogen peroxide was produced in their
non-phagocyte tissue/cell de jour, often in response to a
hormone or growth factor. Nevertheless, the phagocyte
oxidase was usually absent, sometimes leading to the
misidentiﬁcation of the source of ROS as mitochondria or a
side reaction by another enzyme. In addition, the 1990s
gave rise to early clues that ROS might be important in the
pathogenesis of disease states in a range of tissues. Thus,
by the early 2000s, many clinically important ﬁelds were
poised to make the most of the newly discovered Nox
family. This has resulted in a decade of enormous cross-
disciplinary excitement and growth, and has required those
of us who grew up in the ﬁrst Nox epoch to become ﬂuent
in a variety of new clinical ‘‘languages’’.
In the journey from lab bench to bedside, there are a
series of predictable stages through which a scientiﬁc
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123discovery—in this case a group of enzymes—evolves. In
the ﬁrst stage, the basic science is extended in an effort to
understand the fundamental enzymatic or regulatory
mechanisms and protein or ligand interactions. Among
other important ﬁndings for Nox enzymes, this still-ongo-
ing phase has yielded information as to the different modes
of regulation (the new regulatory subunits NOXO1 and
NOXA1, calcium, phosphorylation, controlled expression,
oligomerization, etc.) and structural features (e.g., binding
sites, regulatory domains, etc.) that are important to the
function of Nox enzymes. Such information provides the
foundation for all subsequent stages, including designing
methods to screen for novel inhibitors and characterizing
how these inhibitors work. A second stage attempts to
answer the question: ‘‘What are the normal biological roles
of the Nox isoform(s)’’? In the early 2000s, the new Nox
isoenzymes were somewhat enigmatic in this regard, due to
preconceptions about ‘‘universally harmful effects’’ of
ROS, along with biases from the phagocyte oxidase that
predisposed investigators to interpret their results in terms
of innate immune mechanisms. This second stage catalogs
when and where the enzymes are expressed and/or acti-
vated, and relies heavily on methods to suppress the
expression of a given Nox isoform in cells or animals. The
latter approach has been particularly valuable in estab-
lishing biological roles for Nox isoforms above and beyond
microbial killing; these include chemical modiﬁcation/
stabilization of extracellular matrix (C. elegans), signal
transduction in smooth muscle (Drosophila), gravity per-
ception (mouse), etc. A third evolutionary stage attempts to
deﬁne a role for the enzyme/protein in disease states. This
stage historically can lag the initial discovery by many
years or decades (if it occurs at all!). However, in the case
of Nox enzymes, investigators in many clinically important
ﬁelds had already suspected ROS in pathogenesis, and had
been on the lookout for the enzyme perpetrator(s). Fol-
lowing the identiﬁcation of the Nox Family, suspicion
quickly fell on the Nox isozymes and in some cases spe-
ciﬁc Noxes have been pronounced guilty, based to a large
extent upon animal models of disease. The fourth stage,
after a given enzyme has been incriminated, is to utilize
fundamental information about the enzyme to discover
ways to intervene therapeutically. This usually means
discovering an inhibitor that blocks function, but in some
cases can involve suppression of the enzyme’s expression,
e.g., using RNA interference or other genetic means. When
successful, the outcome is a drug or other therapeutic
method [1, 2]. Given the short history of the Age of the
Nox Family, there is so far no fully developed Nox iso-
form-based therapeutic method. However, several
academic laboratories and/or small pharmaceutical com-
panies are dedicated to this approach and have developed
Nox inhibitors that show selectivity for different Nox
isoenzymes. Indeed, we are aware of one such inhibitor
that is already in phase I clinical trials for diabetic
nephropathy, and more drug candidates will undoubtedly
follow.
This volume summarizes the remarkable progress that
now implicates individual Nox isoforms in a surprising
number of speciﬁc, mostly chronic, diseases. While the
Nox enzymes themselves are unlikely to be the precipi-
tating event, sufﬁcient evidence now exists to accuse them
and their gang of ROS of being key offenders in causing
cell and tissue damage in diverse conditions. This volume
reﬂects this growing appreciation that Nox isoforms par-
ticipate in many diseases, and an expanding interest in
developing Nox-based therapeutics.
With an obvious predilection for quotations from Win-
ston Churchill, the ﬁrst contribution by Iris Dahan and
Edgar Pick, Tel Aviv University, starts with an introduc-
tion into the family of NADPH oxidases followed by the
rational for the identiﬁcation and development of Nox
inhibitors. The authors brieﬂy dip into the history of Nox
inhibitory peptides and then deal with the challenges,
opportunities, and pitfalls of peptide inhibitors in general.
This comprehensive and thoughtful review is a scientiﬁc as
well as literary highlight that sets the stage for the fol-
lowing contributions.
Jamel El-Benna and coworkers, INSERM, Paris, focus
on peptide inhibitors speciﬁc for the phagocyte NADPH
oxidase, Nox2 (previously called gp91phox). The mode of
action is discussed with special emphasis on possible tar-
gets including either Nox2 itself and/or molecules of the
Nox2 activation complex. Furthermore, the challenge of
delivery into living cells is discussed. One option suggested
is the use of cell-penetrating peptides or protein-transduc-
tion domains identiﬁed in the HIV TAT protein or the
antennapedia protein from Drosophila. Eventually, the
beneﬁcial potency of Nox2 inhibitors in inﬂammatory
diseases is highlighted.
The theme of Nox inhibitory peptides is taken up by the
Pagano group, University of Pittsburgh, who start out with
the notion that any of the available inhibitors have proven
non-speciﬁc, falling into the category of scavengers or
inhibitors of more than one source of ROS. They review
some of the efforts that have been undertaken to develop
speciﬁc inhibitors of Nox oxidases over the past decade.
Nox inhibitory peptides such as Nox2ds-tat were valued for
their speciﬁcity. However, the ‘‘druggability’’ of peptides is
generally challenged due to their limited bioavailability,
gut degradation, and inability to cross the plasma mem-
brane of living cells. Given the limitations of peptide-
inhibitor strategies, the search for speciﬁc Nox inhibitors
has returned to small-molecule inhibitors by using high-
throughput screening of diverse libraries. Pagano et al.
discuss a number of compounds recently identiﬁed by HTS
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ML171, thus far proved speciﬁc for one Nox isoform
(Nox1). The development of isoform-speciﬁc Nox inhibi-
tors is considered mandatory for curtailing their many in
vivo effects, which is required for therapeutical applica-
bility. Given the high degree of homology among the
various Nox isoforms in terms of catalytic activity and
structure, the identiﬁcation of isoform-speciﬁc Nox inhib-
itors seems to be a formidable task.
One of these small molecule inhibitors, VAS2870, is
one topic of the contribution by Harald Schmidt and
coworkers, Maastricht University. The review of the liter-
ature characterized VAS2870 as a pan-Nox inhibitor that
blocks the activity of Nox1,-2, and -4 as well as Duox (in
zebraﬁsh). Although the mode of action is obviously non-
speciﬁc for Nox isoforms, VAS2870 is processed further
for preclinical testing. In a second part, this work dwells on
Nox4 as a possible therapeutic target. Based on the
observation that Nox4 knock-out mice do not show an
overt phenotype, the authors ﬁrst suggest that Nox4 inhi-
bition would probably not cause severe complications.
They then dialectically discuss the potential clinical out-
come of Nox4 inhibition in consideration of the protective
roles of Nox4. They conclude that acute ischemic stroke
appears to be one of the most promising and safest indi-
cations for Nox4 inhibition, because prolonged Nox4
inhibition as therapeutic modality for chronic diseases may
compromise the protective role of Nox4 in heart failure and
angiogenesis.
The contribution of Timo Kahles and Ralph Brandes
focuses on reactive oxygen species and NOX enzymes in
ischemic brain injury. The authors point out the apparent
contradiction between the well-established role of ROS in
experimental models of ischemic stroke on one hand, and
the inefﬁcacy of antioxidants on the other hand. The
authors conclude that a clinical translation of the oxidative
stress concept in cerebrovascular disease ‘‘demands
advanced approaches like targeting the source of ROS
generation, not their products.’’ The authors then discuss
the role of ROS in the breakdown of the blood–brain
barrier during ischemia reperfusion injury. They provide a
review on NOX NADPH oxidases in the cerebral vascu-
lature and summarize our present knowledge of the role of
different Nox isoforms. They ﬁnally review ischemic
stroke experiments in NOX-deﬁcient mice as well as data
on stroke therapy with compounds targeting NOX NADPH
oxidases. They conclude that NOX-targeted therapies are
of major interest for future stroke research, but point out
the requirement to develop inhibitors targeting speciﬁc
NOX isoforms.
The contribution of Victor Thannickal and colleagues
focuses on the question of whether NOX inhibitors might
provide a therapeutic avenue for pulmonary ﬁbrosis. The
authors point out that ROS may have very distinct effects
on different cell types. For example, in pulmonary epi-
thelial cells, ROS may lead to cell death, and in contrast, in
ROS, lead to an alteration of cell phenotype and resistance
to apoptosis. Thus, ROS might be involved in two key
aspects of pulmonary ﬁbrosis: epithelial cell apoptosis and
the increase in ﬁbroblasts, in particular myoﬁbroblasts. The
authors discuss that despite the complexity of pulmonary
ﬁbrosis, NOX4 appears to be the predominant source of
ROS in the disease. Yet, there might be a contribution of
NOX2 coming from inﬂammatory cells. There is some
indication for an activity of N-acetyl cysteine in pulmonary
ﬁbrosis, however the authors suggest that NOX4 inhibitors
are the most promising avenue.
The review by Stephanie Carnesecchi and colleagues
focuses on acute lung injury and ARDS (adult respiratory
distress syndrome). The group had previously demon-
strated that, in a mouse model, NOX1 in alveolar epithelial
cells plays an important role in the mediation of hyperoxic
lung damage. Yet, based on a review of the available lit-
erature, they conclude that in ARDS and acute lung injury,
at least three Nox enzymes are involved: NOX1, NOX2,
and NOX4. Both NOX1 and NOX4 might contribute to
epithelial cell death. NOX4, in addition, however, is likely
to also be involved in ﬁbroblast proliferation and ﬁbrotic
responses. Finally, NOX2 is probably most important in
ARDS-associated inﬂammatory responses. Thus, it is pos-
sible that large-spectrum Nox inhibitors might be most
efﬁcient in acute lung injury and ARDS.
The review by Silvia Sorce and colleagues provides an
overview of the opportunities for NOX inhibitors to treat
diseases of the central nervous system. The authors discuss
the role of NOX overactivity in a variety of CNS diseases,
from amyotrophic lateral sclerosis to schizophrenia. They
also point out that in autoimmune diseases of the central
nervous system, insufﬁcient Nox activity might be the
cause of an overshooting immune response. They then give
an overview of compounds that could be used to target
ROS and NOX enzymes in the CNS. They summarize
experience with antioxidants, natural compounds, as well
as chemically synthesized small molecules. They ﬁnally
discuss the hurdles that need to be overcome before NOX
inhibition can become clinical reality.
The review of Michael Surace and Michelle Block
focuses on microglia-mediated neurotoxicity. Microglial
cells are professional phagocytes of the central nervous
system and hence important cells involved in the host
defense and probably also in the removal of unwanted
material. Yet, an excessive activity of microglia may also
lead to damage of the surrounding brain cells, with NOX2-
derived ROS being one of the key neurotoxic mechanisms.
The authors focus particularly on the role of NOX2 and
microglia in Alzheimer’s disease and in Parkinson’s
NOX enzymes as drug targets 2281
123disease. Both pathologies are characterized by a marked
neuroinﬂammation, including microglia activation. The
authors describe the experimental impact of available
compounds with NOX inhibitory activity, and ﬁnish with
the description of the potential of speciﬁc NOX inhibitors
for neuroinﬂammatory diseases and neurodegeneration.
The review of Rybak and colleagues focuses on the
ROS-mediated damage of the inner ear as a cause of
hearing loss. More speciﬁcally, the authors describe
experiments performed with the chemotherapeutic agent
cisplatin, a clinically important drug whose usefulness is
limited by its ototoxicity. The authors have previously
demonstrated that cisplatin-mediated ototoxicity is due to
NOX3-dependent ROS generation. Importantly, trans-
tympanic injection of siRNA directed against NOX3 pro-
tects against cisplatin-induced hearing loss in animal
models. The authors conclude that NOX3 inhibition might
be a promising way to protect the inner ear from insult, not
only from cisplatin, but also from other ototoxic com-
pounds, and even from noise- and age-induced damage.
Michael Bonner and Jack Arbiser ﬁnally discuss which
inﬂammatory and malignant disorders can be targeted by
NOX inhibitors. This review elucidates the mechanisms of
carcinogenetic and inﬂammatory action of reactive oxygen.
These authors emphasize the need to identify ROS-driven
phenotypes in speciﬁc cancer entities and inﬂammatory
diseases, because pathologic conditions that are charac-
terized by excessive ROS production will likely be
responsive to ROS inhibitors, while conditions with
defective ROS production may be responsive to ROS
inducers.
In summary, there is an emerging new ﬁeld of phar-
macology, namely NOX inhibitors. A wide spectrum of
compounds, from large spectrum NOX inhibitors to iso-
form-speciﬁc inhibitors is likely to emerge. As NOX-
derived ROS are important disease modiﬁers in many
pathologies, NOX inhibitors might become clinically
important drugs in the future.
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